|
STING Agonist 8803 for Blood-Brain Barrier Opening in Glioblastoma Treatment
SHORT DESCRIPTION
Chemical compound that opens the blood-brain barrier to enhance delivery of therapeutics for treating glioblastoma.
INVENTORS
Amy Heimberger*
Northwestern University Feinberg School of Medicine, Department of Neurological Surgery
* Principal Investigator
NU 2025-212
IP STATUS
US...
Published: 4/27/2026
|
Updated: 4/27/2026
|
Inventor(s):
Keywords(s): AD - Alzheimer’s Disease, Adjunct therapy, ALS - Amyotrophic Lateral Sclerosis, Animal Model, Autoimmune disease, Cancer/Oncology, CNS - Central Nervous System, Drug delivery, Immunology, Immunotherapy, MS - Multiple Sclerosis, Neurodegenerative disease, Neurologic disease, PD - Parkinson's Disease, Repurposed Drugs, Research tool, Small molecule, Targeted therapy, TBI - Traumatic brain injury
Category(s): Life Sciences > Therapeutics, Life Sciences > Biomarkers & Biomedical Research Tools
|
|
Targeting IL-6 pathway to treat high risk myelodysplastic syndromes
NU 2022-093
INVENTORS
Peng Ji*
Kehan Ren
Yang Mei
SHORT DESCRIPTION
A method of inhibiting progression of high-risk myelodysplastic syndrome (MDS) or low blast count acute myeloid leukemia (AML) using an inhibitor of IL6 signaling.
BACKGROUND
Approximately 20,000 people in the US are diagnosed with myelodysplastic syndrome (MDS) each year....
Published: 2/17/2026
|
Updated: 2/17/2026
|
Inventor(s):
Keywords(s): AML - Acute myeloid leukemia, Repurposed Drugs, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Targeted Therapy for Glioblastoma via Purine Metabolism Modulation
NU 2019-086
INVENTORS
Atique Ahmed*
Cheol Park
Jack Shireman
SHORT DESCRIPTION
This technology introduces a targeted approach for glioblastoma treatment that modulates purine biosynthesis by targeting the ARL13B-IMPDH2 interaction using repurposed FDA-approved and internationally-used drugs.
BACKGROUND
Glioblastoma is an incurable, aggressive...
Published: 2/6/2026
|
Updated: 6/20/2025
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Cancer/Oncology, Repurposed Drugs, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Repurposing Bumetanide to Address Cognitive Deficits in Schizophrenia
NU 2019-067
INVENTORS
Herbert Y. Meltzer
SHORT DESCRIPTION
Repurposing bumetaide to treat cognitive deficits in schizophrenia syndrome.
ABSTRACT
Cognitive deficits associated with schizophrenia syndrome are the components that contribute most to a low quality of life. While current pharmacological treatments have beneficial effects on treating...
Published: 12/16/2025
|
Updated: 5/30/2023
|
Inventor(s):
Keywords(s): Neurologic disease, Neurology, PSD - Psychotic spectrum disorder, Repurposed Drugs, Schizophrenia, Small molecule, Therapeutics
Category(s): Life Sciences > Therapeutics
|